IRB #

STUDY00019738

Title

An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer

Principal Investigator

Jacqueline Vuky

Study Purpose

The purpose of this study is to determine if balixafortide combined with eribulin is well tolerated and more effective for treating breast cancer compared with eribulin given alone.

Medical Condition(s)

Breast Cancer, HER2 negative

Eligibility Criteria

- Metastatic Breast Cancer currently of stage IV disease

- At least 14 days from the completion of any previous cancer therapy
Adequate organ function

- Life expectancy of 3 months or more

- Willing and able to comply with the protocol and able to understand and willing to sign an informed consent

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Up to 60 months

Minors Included

No

Contact

OHSU Knight Cancer Institute Cancer Clinical Trials

Email: trials@ohsu.edu

Phone: 503-494-1080

Sponsor

Polyphor, Ltd

Recruitment End

03/01/2022

Compensation Provided

No


Go Back